Related references
Note: Only part of the references are listed.Oligorecurrent Nodal Prostate Cancer Long-term Results of an Elective Nodal Irradiation Approach
Sebastien Tran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley et al.
CELL (2018)
Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer
Matthijs Cysouw et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer
Carlo Cattrini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
1 STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer
Ryan M. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Yes or no to local therapy for oligometastatic prostate cancer?
Judd W. Moul
NATURE REVIEWS UROLOGY (2018)
Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression
Catherine A. Pembroke et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial
Marco Trovo et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Sean P. Pitroda et al.
NATURE COMMUNICATIONS (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
Johann S. De Bono et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer
Ciro Franzese et al.
CANCER MEDICINE (2018)
The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients
O. C. Guler et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?
Won Sik Jang et al.
BJU INTERNATIONAL (2018)
Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer
Guilhem Roubaud et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations
Jeffrey J. Tosoian et al.
NATURE REVIEWS UROLOGY (2017)
Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience
Gianluca Ingrosso et al.
WORLD JOURNAL OF UROLOGY (2017)
Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up
Giorgio Gandaglia et al.
EUROPEAN UROLOGY (2017)
Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience
Andrew J. Erie et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Salvage Pelvic Lymph Node Dissection after Radical Prostatectomy for Biochemical and Lymph Node Recurrence
Charlotte Peeters et al.
UROLOGIA INTERNATIONALIS (2017)
Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology
Gregory A. Joice et al.
CURRENT OPINION IN UROLOGY (2017)
Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
Giulia Riva et al.
ECANCERMEDICALSCIENCE (2017)
11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer
Ciro Franzese et al.
CANCER INVESTIGATION (2017)
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy
Aurelie De Bruycker et al.
BJU INTERNATIONAL (2017)
Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT
Esther W. Bouman-Wammes et al.
CLINICAL GENITOURINARY CANCER (2017)
Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report
Mark C. Markowski et al.
CLINICAL GENITOURINARY CANCER (2017)
Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited
Amila Siriwardana et al.
BJU INTERNATIONAL (2017)
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
Noura Radwan et al.
BMC CANCER (2017)
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
Luca Triggiani et al.
BRITISH JOURNAL OF CANCER (2017)
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)
Gregor Habl et al.
BMC CANCER (2017)
Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer
M. I. Martinez-Fernandez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report
Chiachien Jake Wang et al.
ONCOLOGY LETTERS (2016)
Stereotactic body radiotherapy for oligoprogressive cancer
Patrick Cheung
BRITISH JOURNAL OF RADIOLOGY (2016)
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)
Anthony C. Wong et al.
CANCER (2016)
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences
P. Ost et al.
CLINICAL ONCOLOGY (2016)
A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation
Prasanna Sooriakumaran et al.
EUROPEAN UROLOGY (2016)
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis
Piet Ost et al.
EUROPEAN UROLOGY (2016)
Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer
Jonathan L. Muldermans et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer
Andrea B. Apolo et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M. Duchesne et al.
LANCET ONCOLOGY (2016)
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
Steven P. Rowe et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Increasing incidence of metastatic prostate cancer in the United States (2004-2013)
A. B. Weiner et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results
Francesco Pasqualetti et al.
RADIATION ONCOLOGY (2016)
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial
Swetha Sridharan et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer
Francesco Pasqualetti et al.
ONCOLOGY RESEARCH AND TREATMENT (2016)
Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy
Fabio Zattoni et al.
EUROPEAN UROLOGY FOCUS (2016)
Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience
Elisabetta Ponti et al.
CLINICAL GENITOURINARY CANCER (2015)
18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse A Comparison to 11C-Choline PET/CT
Cristina Nanni et al.
CLINICAL NUCLEAR MEDICINE (2015)
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Paul L. Nguyen et al.
EUROPEAN UROLOGY (2015)
Survival with Newly Diagnosed Metastatic Prostate Cancer in the Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James et al.
EUROPEAN UROLOGY (2015)
Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer
Ryogo Minamimoto et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study
Axel Heidenreich et al.
JOURNAL OF UROLOGY (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Matthew K. H. Hong et al.
NATURE COMMUNICATIONS (2015)
14q32-encoded microRNAs mediate an oligometastatic phenotype
Abhineet Uppal et al.
ONCOTARGET (2015)
Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome
Tom Claeys et al.
BIOMED RESEARCH INTERNATIONAL (2015)
SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer
Gregory Azzam et al.
FRONTIERS IN ONCOLOGY (2015)
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs
Abhineet Uppal et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
The oligometastatic state-separating truth from wishful thinking
David A. Palma et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Karel Decaestecker et al.
RADIATION ONCOLOGY (2014)
Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases
Ulrike Schick et al.
ACTA ONCOLOGICA (2013)
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy
M. T. Schweizer et al.
ANNALS OF ONCOLOGY (2013)
Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy
Patrick Berkovic et al.
CLINICAL GENITOURINARY CANCER (2013)
The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis
Martin H. Umbehr et al.
EUROPEAN UROLOGY (2013)
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
Kamran A. Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity?
Tom Treasure
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2012)
Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
Kaiyumars Contractor et al.
CLINICAL CANCER RESEARCH (2011)
High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials
Donald A. Berry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Oligometastases revisited
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months
Filippo Alongi et al.
TUMORI JOURNAL (2010)
Systemic effects of local radiotherapy
Silvia C. Formenti et al.
LANCET ONCOLOGY (2009)
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET
Hossein Jadvar
NATURE REVIEWS UROLOGY (2009)
Androgen-independent prostate cancer treated with resection of the solitary metastatic site
Raj S. Pruthi et al.
UROLOGIA INTERNATIONALIS (2007)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
Is there a favorable subset of patients with prostate cancer who develop oligometastases?
D Singh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
MG Harisinghani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
